Physician profile
Muhammad A Baig
NPI 1730355256
$1,009.58
in general payments reported to CMS, 2019-2025
19 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $167 · 2021: $76.98 · 2022: $21.35 · 2023: $51.16 · 2024: $186 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.71 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $262.29 | 2019-2025 | Jynarque |
| Boston Scientific Corporation | $114.91 | 2024 | Spyglass |
| Novartis Pharmaceuticals Corporation | $71.33 | 2024-2025 | |
| Amgen INC. | $70.62 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $60.06 | 2023-2025 | Lokelma, Farxiga |
| Mallinckrodt Enterprises LLC | $52.97 | 2019 | |
| Novo Nordisk INC | $52.91 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $52.15 | 2019-2022 | |
| Scpharmaceuticals INC. | $47.42 | 2025 | |
| Genzyme Corporation | $44.04 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $29.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.40 | 2024 | Crysvita |
| Akebia Therapeutics INC | $24.52 | 2019-2025 | Vafseo |
| Natus Medical Incorporated | $19.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.10 | 2025 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $17.70 | 2020 | |
| Kyowa Kirin, INC. | $16.73 | 2025 | |
| Ardelyx, INC. | $15.29 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.